Thermo Fisher Scientific and Cedars-Sinai have announced a collaboration to develop a pathway to precision medicine through the development of robust, reliable, and sensitive LC–MS-based workflows for clinical research applications.
Thermo Fisher Scientific (Waltham, Massachusetts, USA) and Cedars-Sinai (Los Angeles, California, USA) have announced a collaboration to develop a pathway to precision medicine through the development of robust, reliable, and sensitive liquid chromatography–mass spectrometry (LC–MS)-based workflows for clinical research applications.
“Thermo Fisher shares our vision for helping clinical research teams set new standards for excellence and innovation in patient care through precision medicine. The goal is to develop advanced
LC–MSâbased workflows for the untargeted screening and targeted quantitation of protein-based biomarkers for critical disease states, which hold the potential to benefit not only our own patients but also the wider clinical community,” said Jennifer Van Eyk, Ph.D., Principal Investigator for Research and Director of the Advanced Clinical Biosystems Institute in the Department of Biomedical Sciences at Cedars-Sinai.
For more information, please visit www.thermofisher.com/BeSure
Targeted Blood Lipidomics of Colorectal Cancer: An HTC-18 Interview with Jef Focant
July 26th 2024At HTC-18 in Leuven, Executive Editor of LCGC International, Alasdair Matheson, spoke to Jef Focant from the University of Liege about his talk entitled, “Targeted Blood Lipidomics of Colorectal Cancer."
Carol Robinson Awarded 2024 Lifetime Achievement European Inventor Award
July 24th 2024Carol Robinson of the University of Oxford has received the European Inventor Award 2024 for Lifetime Achievement from the European Patent Office for her work bringing mass spectrometry to structural biology.